Jaguar Health, Inc.
For the period ended Jun 30, 2026. Filed Aug 19, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 19, 2026
JAGX$0.44+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended · Six Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|
| June 30, · June 30, | ||||||||
| (In thousands, except share and per share data) · 2026 · 2025 · 2026 · 2025 | ||||||||
| License revenue | $ | 43 | $ | 43 | $ | 19,086 | $ | 86 |
| Product revenue, net | 1,182 | 2,936 | 2,386 | 5,107 | ||||
| Grant revenue | — | — | 25 | — | ||||
| Total revenue, net | 1,225 | 2,979 | 21,497 | 5,193 | ||||
| Operating expenses | ||||||||
| Cost of product revenue | 1,031 | 527 | 2,189 | 1,042 | ||||
| Research and development | 3,336 | 3,265 | 7,264 | 6,995 | ||||
| Sales and marketing | 5 | 2,467 | 901 | 4,960 | ||||
| General and administrative | 4,450 | 4,727 | 8,558 | 9,624 | ||||
| Total operating expenses | 8,822 | 10,986 | 18,912 | 22,621 | ||||
| Income (loss) from operations | (7,597) | (8,007) | 2,585 | (17,428) | ||||
| Loss on extinguishment of debt | (3,504) | (1,822) | (4,132) | (1,822) | ||||
| Changes in fair value of freestanding and hybrid financial instruments designated at Fair Value Option | (1,918) | (1,068) | (2,255) | (2,411) | ||||
| Interest income (expense) | (161) | 15 | (860) | 71 | ||||
| Other income (expense) | 378 | 322 | 583 | 434 | ||||
| Income (loss) before income tax expense | (12,802) | (10,560) | (4,079) | (21,156) | ||||
| Income tax expense | — | — | — | — | ||||
| Net loss before equity in net loss of joint venture | (12,802) | (10,560) | (4,079) | (21,156) | ||||
| Equity in net loss of joint venture | — | — | — | — | ||||
| Net income (loss) | $ | (12,802) | $ | (10,560) | $ | (4,079) | $ | (21,156) |
| Net loss attributable to noncontrolling interest | $ | (120) | $ | (153) | $ | (246) | $ | (285) |
| Stock dividends to preferred stockholders | $ | — | $ | — | $ | 9,470 | $ | — |
| Deemed dividend to preferred stockholders | $ | 8 | $ | — | $ | 6,071 | $ | — |
| Preferred returns to preferred stockholders | $ | — | $ | — | $ | 331 | $ | — |
| Cumulative preferred dividends allocated to preferred stockholders | $ | 11 | $ | — | $ | 11 | $ | — |
| Net loss attributable to common stockholders | $ | (12,701) | $ | (10,407) | $ | (19,716) | $ | (20,871) |
| Net loss per share, basic and diluted | $ | (15.70) | $ | (358.94) | $ | (35.11) | $ | (937.26) |
| Weighted-average common stock outstanding, basic and diluted | 809,122 | 28,994 | 561,567 | 22,268 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.